Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell Lung Cancer Improves Survival

Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell... ORIGINAL ARTICLE Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell Lung Cancer Improves Survival Masayuki Tanahashi, MD, Hiroshi Niwa, MD, Haruhiro Yukiue, MD, Eriko Suzuki, MD, Hiroshi Haneda, MD, and Naoko Yoshii, MD ung cancer is the leading cause of cancer death in many Background: In this study, we analyzed the usefulness of adjuvant Lcountries. Surgery is the best potentially curative treatment chemotherapy for non-small cell lung cancer based on the histocul- modality for patients with non-small cell lung cancer (NSCLC). ture drug response assay (HDRA). NSCLC accounts for about 80 to 85% of all lung cancer. Methods: From September 2001 to December 2008, 65 patients Although the discovery rate of early-stage lung cancer has with pathologic stage II or higher non-small cell lung cancer who increased due to the spread of computed tomography-based underwent surgery received two-cycle HDRA-based adjuvant che- checkup, lung cancer discovered at an advanced stage is still motherapy. Chemosensitivity to cisplatin, carboplatin, paclitaxel, common. Moreover, it has been reported that the greater part of docetaxel, gemcitabine, and irinotecan was examined by the HDRA. relapse in patients who have undergone complete resection All patients were classified according to the number http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell Lung Cancer Improves Survival

Journal of Thoracic Oncology , Volume 5 (9) – Sep 1, 2010

Loading next page...
 
/lp/wolters-kluwer-health/adjuvant-chemotherapy-based-on-the-in-vitro-histoculture-drug-response-UrrX1XnmS7

References (39)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181e7d035
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell Lung Cancer Improves Survival Masayuki Tanahashi, MD, Hiroshi Niwa, MD, Haruhiro Yukiue, MD, Eriko Suzuki, MD, Hiroshi Haneda, MD, and Naoko Yoshii, MD ung cancer is the leading cause of cancer death in many Background: In this study, we analyzed the usefulness of adjuvant Lcountries. Surgery is the best potentially curative treatment chemotherapy for non-small cell lung cancer based on the histocul- modality for patients with non-small cell lung cancer (NSCLC). ture drug response assay (HDRA). NSCLC accounts for about 80 to 85% of all lung cancer. Methods: From September 2001 to December 2008, 65 patients Although the discovery rate of early-stage lung cancer has with pathologic stage II or higher non-small cell lung cancer who increased due to the spread of computed tomography-based underwent surgery received two-cycle HDRA-based adjuvant che- checkup, lung cancer discovered at an advanced stage is still motherapy. Chemosensitivity to cisplatin, carboplatin, paclitaxel, common. Moreover, it has been reported that the greater part of docetaxel, gemcitabine, and irinotecan was examined by the HDRA. relapse in patients who have undergone complete resection All patients were classified according to the number

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2010

There are no references for this article.